Blacksmith Medicines is using its purpose-built platform for metalloenzyme-targeted medicines to rationally design small molecule inhibitors for novel targets in immuno-oncology and inflammatory diseases. The company, which is a spin-out of Forge Therapeutics, was officially launched in early 2021 with seed funding and a research collaboration with Eli Lilly and Company. Blacksmith Medicines’ platform is […]

View post to subscribe to site newsletter.

Ambagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagon says its approach opens up novel target space as well as having an innovative mechanism of action. Protein–protein interactions (PPIs) are one of the core processes by which cells function and interact with their environment, making them […]

View post to subscribe to site newsletter.